Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.

Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD.

Br J Haematol. 2019 Sep;186(6):801. doi: 10.1111/bjh.16048. Epub 2019 Jun 17. No abstract available.

PMID:
31206598
2.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE.

Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.

PMID:
31088841
3.

Maintenance therapy in acute myeloid leukemia: What is the future?

McMahon CM, Luger SM.

Semin Hematol. 2019 Apr;56(2):102-109. doi: 10.1053/j.seminhematol.2018.08.006. Epub 2018 Aug 28. Review.

PMID:
30926085
4.

Relapsed T Cell ALL: Current Approaches and New Directions.

McMahon CM, Luger SM.

Curr Hematol Malig Rep. 2019 Apr;14(2):83-93. doi: 10.1007/s11899-019-00501-3. Review.

PMID:
30880359
5.

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP.

Leuk Res. 2019 Mar;78:29-33. doi: 10.1016/j.leukres.2019.01.007. Epub 2019 Jan 17.

6.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18.

PMID:
30658992
7.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.

8.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.

Am J Hematol. 2019 Jan;94(1):111-117. doi: 10.1002/ajh.25333. Epub 2018 Nov 15.

PMID:
30370956
9.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, Porter DL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):515-521. doi: 10.1016/j.bbmt.2018.09.034. Epub 2018 Oct 10.

PMID:
30315941
10.

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, Stadtmauer EA, Porter DL.

Clin Infect Dis. 2019 May 30;68(12):2003-2009. doi: 10.1093/cid/ciy822.

PMID:
30256954
11.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25162. [Epub ahead of print]

12.

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.

Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL.

Bone Marrow Transplant. 2019 Feb;54(2):212-217. doi: 10.1038/s41409-018-0236-z. Epub 2018 May 24.

PMID:
29795429
13.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Nov;59(11):2723-2726. doi: 10.1080/10428194.2018.1452219. Epub 2018 Apr 18. No abstract available.

PMID:
29667455
14.

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE.

Invest New Drugs. 2018 Aug;36(4):657-666. doi: 10.1007/s10637-018-0585-x. Epub 2018 Apr 2.

15.

Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.

Crisalli LM, Hinkle JT, Walling CC, Sell M, Frey NV, Hexner EO, Loren AW, Luger SM, Stadtmauer EA, Porter DL, Reshef R.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1203-1208. doi: 10.1016/j.bbmt.2018.01.037. Epub 2018 Feb 2.

16.

How can one optimize induction therapy in AML?

Luger SM.

Best Pract Res Clin Haematol. 2017 Dec;30(4):301-305. doi: 10.1016/j.beha.2017.10.001. Epub 2017 Oct 4. Review.

PMID:
29156199
17.

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Litzow MR, Fielding AK, Luger SM, Paietta E, Ofran Y, Rowe JM, Goldstone AH, Tallman MS, Lazarus HM.

Bone Marrow Transplant. 2017 Dec;52(12):1592-1598. doi: 10.1038/bmt.2017.110. Epub 2017 Jun 5. Review.

PMID:
28581459
18.

Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS; ECOG-ACRIN Cancer Research Group.

Leuk Res. 2017 Aug;59:55-64. doi: 10.1016/j.leukres.2017.05.010. Epub 2017 May 12.

19.

Minimal Residual Disease in Acute Myeloid Leukemia.

Sung PJ, Luger SM.

Curr Treat Options Oncol. 2017 Jan;18(1):1. doi: 10.1007/s11864-017-0447-3. Review.

PMID:
28110381
20.

High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.

Tasian SK, Hurtz C, Wertheim GB, Bailey NG, Lim MS, Harvey RC, Chen IM, Willman CL, Astles R, Zebrowski A, Reshmi SC, Li MM, Frey NV, Luger SM, Carroll M, Perl AE.

Leukemia. 2017 Apr;31(4):981-984. doi: 10.1038/leu.2016.375. Epub 2016 Dec 9. No abstract available.

21.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG.

Nat Commun. 2016 Nov 8;7:13331. doi: 10.1038/ncomms13331.

22.

Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

Kumar AJ, Gimotty PA, Gelfand JM, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, Litzow M, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW.

Am J Hematol. 2016 Nov;91(11):1107-1112. doi: 10.1002/ajh.24497. Epub 2016 Aug 22. Erratum in: Am J Hematol. 2017 May;92 (5):E85.

23.

Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS.

Acta Haematol. 2016;136(4):210-218. Epub 2016 Sep 16.

24.

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Wiernik PH, Tallman MS.

J Clin Oncol. 2016 Oct 10;34(29):3544-3553. Erratum in: J Clin Oncol. 2017 Jan 10;35(2):263.

25.

Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.

Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1961-1967. doi: 10.1016/j.bbmt.2016.07.018. Epub 2016 Jul 28.

26.

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.

Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB.

JCI Insight. 2016 Jun 16;1(9). pii: e87323.

27.

Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation.

Yam C, Crisalli L, Luger SM, Loren AW, Hexner EO, Frey NV, Mangan JK, Gao A, Stadtmauer EA, Porter DL, Reshef R.

Am J Hematol. 2016 Sep;91(9):883-7. doi: 10.1002/ajh.24424. Epub 2016 Jul 12.

28.

A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.

Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M.

PLoS One. 2016 Apr 6;11(4):e0153016. doi: 10.1371/journal.pone.0153016. eCollection 2016.

29.

Allogeneic transplant for FLT3-ITD+ AML: room for improvement.

Perl AE, Luger SM.

Bone Marrow Transplant. 2016 Apr;51(4):508-10. doi: 10.1038/bmt.2016.37. Epub 2016 Mar 14. No abstract available.

PMID:
26974268
30.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, Levine BL, June CH, Emerson SG, Porter DL.

Am J Hematol. 2016 May;91(5):453-60. doi: 10.1002/ajh.24303. Epub 2016 Apr 4.

31.

Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.

Kumar AJ, Vassilev P, Loren AW, Luger SM, Reshef R, Gill S, Smith J, Goldstein SC, Hexner E, Stadtmauer EA, Porter D, Frey NV.

Am J Hematol. 2016 Jun;91(4):426-9. doi: 10.1002/ajh.24308.

32.

Revisiting maintenance therapy in acute myeloid leukemia with novel agents.

Canaani J, Luger SM.

Curr Opin Hematol. 2016 Mar;23(2):175-80. doi: 10.1097/MOH.0000000000000223. Review.

PMID:
26766539
33.

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM.

Blood. 2016 Mar 24;127(12):1551-8. doi: 10.1182/blood-2015-07-657403. Epub 2016 Jan 11.

34.

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Zent CS, Victoria Wang X, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS.

Am J Hematol. 2016 Mar;91(3):308-12. doi: 10.1002/ajh.24265. Epub 2016 Feb 9.

35.

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.

Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV.

Br J Haematol. 2016 Jul;174(2):332-4. doi: 10.1111/bjh.13771. Epub 2015 Sep 25. No abstract available.

PMID:
26403537
36.

Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey.

Lee EJ, Smith BD, Merrey JW, Lee AI, Podoltsev NA, Barbarotta L, Litzow MR, Prebet T, Luger SM, Gore S, Streiff MB, Zeidan AM.

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):766-770. doi: 10.1016/j.clml.2015.07.637. Epub 2015 Aug 6.

37.

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathan M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA Jr, Wirk B, Pérez WS, Batiwalla M, Weisdorf DJ.

Biol Blood Marrow Transplant. 2016 Feb;22(2):248-257. doi: 10.1016/j.bbmt.2015.08.024. Epub 2015 Aug 29.

38.

Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.

Paul TM, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Nasta SD, Loren A, Frey N, Perl A, Cohen AD, Weiss BM, Stadtmauer EA, Vogl DT.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):536-40. doi: 10.1016/j.clml.2015.05.006. Epub 2015 Jun 6.

PMID:
26141214
39.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL.

J Clin Oncol. 2015 Jul 20;33(21):2392-8. doi: 10.1200/JCO.2014.60.1203. Epub 2015 Jun 8.

40.

How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.

Frey NV, Luger SM.

Blood. 2015 Jul 30;126(5):589-96. doi: 10.1182/blood-2014-09-551937. Epub 2015 May 12.

41.

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

DiPersio JF, Erba HP, Larson RA, Luger SM, Tallman MS, Brill JM, Vuagniaux G, Rouits E, Sorensen JM, Zanna C.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):443-9. doi: 10.1016/j.clml.2015.02.020. Epub 2015 Mar 5.

42.

Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy.

Singh N, Qayyum S, Wasik MA, Luger SM.

Am J Hematol. 2015 Oct;90(10):964-5. doi: 10.1002/ajh.23987. Epub 2015 Apr 29. No abstract available.

43.

Approach to patients with primary refractory acute myeloid leukemia.

Orlowski RJ, Mangan JK, Luger SM.

Curr Opin Hematol. 2015 Mar;22(2):97-107. doi: 10.1097/MOH.0000000000000115. Review.

PMID:
25575037
44.

Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition.

Bagley SJ, Sehgal AR, Gill S, Frey NV, Hexner EO, Loren AW, Mangan JK, Porter DL, Stadtmauer EA, Reshef R, Luger SM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):768-71. doi: 10.1016/j.bbmt.2014.12.005. Epub 2014 Dec 24.

45.

A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.

Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ.

Blood. 2015 Jan 22;125(4):680-6. doi: 10.1182/blood-2014-09-595744. Epub 2014 Dec 2.

46.

Dynamic evolution of clonal epialleles revealed by methclone.

Li S, Garrett-Bakelman F, Perl AE, Luger SM, Zhang C, To BL, Lewis ID, Brown AL, D'Andrea RJ, Ross ME, Levine R, Carroll M, Melnick A, Mason CE.

Genome Biol. 2014 Sep 27;15(9):472. doi: 10.1186/s13059-014-0472-5.

47.

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10.

48.

Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients.

Watts JM, Wang XV, Litzow MR, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D, Zickl L, Paietta E, Rowe JM, Tallman MS.

Leuk Res. 2014 Aug;38(8):901-6. doi: 10.1016/j.leukres.2014.05.018. Epub 2014 Jun 2.

49.

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

Pratz KW, Luger SM.

Curr Opin Hematol. 2014 Mar;21(2):72-8. doi: 10.1097/MOH.0000000000000022. Review.

50.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH.

Blood. 2014 Feb 6;123(6):843-50. doi: 10.1182/blood-2013-09-529008. Epub 2013 Nov 25.

Supplemental Content

Loading ...
Support Center